Payment overview · 2025
General Payments
$3,081.85
116 reported records · 22 companies
Healthcare provider profile · identity verified
Rita Goldvug, M.D
Allopathic & Osteopathic Physicians|Internal Medicine · REGO PARK, NY · NPI 1447296421
Verified facts
What the public records show
CMS Open Payments records show Rita Goldvug, M.D received $3,081.85 in general payments during 2025 across 116 reported records.
AstraZeneca Pharmaceuticals LP accounted for 20.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 37 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Airsupra, Creon, Eliquis, Farxiga, Linzess, Nurtec Odt, Otezla, Ozempic, Prolia, Qulipta, Rybelsus, Trelegy Ellipta, Ubrelvy, Zenpep, Ztlido.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 171 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 376 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 208 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Ubrelvy by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 145 claims for Zenpep by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OTEZLA as an associated drug or biological on 177267 records involving 48600 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Otezla by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Prolia by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AIRSUPRA as an associated drug or biological on 165148 records involving 56069 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Airsupra by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Nexium by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Symbicort by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 306 claims for Eliquis by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLIZET as an associated drug or biological on 63 records involving 47 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Nexlizet by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 168 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 306 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Nurtec Odt by this doctor in 2024.
SCILEX PHARMACEUTICALS INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZTLido as an associated drug or biological on 6923 records involving 3060 distinct recipient NPIs. Public Medicare Part D data also shows 107 claims for Ztlido by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULANCE as an associated drug or biological on 2652 records involving 1501 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Trulance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $640.53 | 20.8% | 22 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $478.01 | 15.5% | 15 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $453.72 | 14.7% | 19 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $378.96 | 12.3% | 13 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $183.99 | 6.0% | 7 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $170.13 | 5.5% | 7 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $125.10 | 4.1% | 4 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $124.74 | 4.0% | 5 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $93.97 | 3.0% | 5 | 2025 |
| SCILEX PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $76.94 | 2.5% | 4 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $70.91 | 2.3% | 3 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $51.51 | 1.7% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $28.38 | 0.9% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $28.34 | 0.9% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $25.58 | 0.8% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $25.04 | 0.8% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $23.53 | 0.8% | 1 | 2025 |
| IBSA Pharma Inc. | Unresolved — no canonical attribution shown | $22.91 | 0.7% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $21.63 | 0.7% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.30 | 0.7% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.92 | 0.6% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $17.71 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,076.85 | 115 |
| Education | $5.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $378.96 | 13 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $266.22 | 8 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $261.04 | 11 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $257.09 | 9 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $257.09 | 9 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $221.99 | 8 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $204.26 | 8 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $183.99 | 7 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $125.10 | 4 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $124.74 | 5 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $123.53 | 5 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $119.28 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $115.95 | 7 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $96.79 | 4 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $95.92 | 5 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $93.97 | 5 | 2025 |
Source payment records
|
|||||
| ZTLido Normalized: ztlido |
Drug | SCILEX PHARMACEUTICALS INC. | $76.94 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $76.45 | 3 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $73.70 | 4 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $72.83 | 3 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $70.91 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $61.86 | 2 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $51.51 | 2 | 2025 |
Source payment records
|
|||||
| VOWST Normalized: vowst |
Biological | Aimmune Therapeutics, Inc. | $50.85 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $49.70 | 4 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $28.38 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $28.34 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $25.58 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $25.04 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $23.53 | 1 | 2025 |
Source payment records
|
|||||
| Flector Normalized: flector |
Drug | IBSA Pharma Inc. | $22.91 | 1 | 2025 |
Source payment records
|
|||||
| Licart Normalized: licart |
Drug | IBSA Pharma Inc. | $22.91 | 1 | 2025 |
Source payment records
|
|||||
| Tirosint Normalized: tirosint |
Drug | IBSA Pharma Inc. | $22.91 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $21.63 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $21.30 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $18.92 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $17.71 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AIRSUPRA airsupra |
2025 | Airsupra | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| CREON creon |
2025 | Creon | 2024 | 171 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 306 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 84 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 376 | exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 73 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| OTEZLA otezla |
2025 | Otezla | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 168 | exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 39 | exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 60 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 145 | exact normalized | Medicare Part D |
| ZTLido ztlido |
2025 | Ztlido | 2024 | 107 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
171 | 28 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
376 | 54 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
208 | 34 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
145 | 28 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | OTEZLA open payments reported associated product |
CMS Open Payments — General Payments 177267 supporting records · 48600 recipient NPIs · example record 1226871616 |
Otezla · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
39 | 26 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
96 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | AIRSUPRA open payments reported associated product |
CMS Open Payments — General Payments 165148 supporting records · 56069 recipient NPIs · example record 1206131344 |
Airsupra · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
84 | 16 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
92 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
56 | 15 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
306 | 45 |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLIZET open payments reported associated product |
CMS Open Payments — General Payments 63 supporting records · 47 recipient NPIs · example record 1243951667 |
Nexlizet · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
60 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
168 | 25 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
306 | 45 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
73 | suppressed by CMS |
| SCILEX PHARMACEUTICALS INC. Exact reporting entity; no affiliate inference |
2025 | ZTLido open payments reported associated product |
CMS Open Payments — General Payments 6923 supporting records · 3060 recipient NPIs · example record 1242585247 |
Ztlido · 2024 Exact normalized brand match · 1 Part D row |
107 | 22 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | TRULANCE open payments reported associated product |
CMS Open Payments — General Payments 2652 supporting records · 1501 recipient NPIs · example record 1231775445 |
Trulance · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 1207 | 208 |
| Amlodipine Besylate | Amlodipine Besylate | 1068 | 182 |
| Famotidine | Famotidine | 1068 | 188 |
| Metoprolol Succinate | Metoprolol Succinate | 1042 | 163 |
| Losartan Potassium | Losartan Potassium | 935 | 153 |
| Metformin Hcl | Metformin Hcl | 777 | 122 |
| Atorvastatin Calcium | Atorvastatin Calcium | 638 | 98 |
| Escitalopram Oxalate | Escitalopram Oxalate | 450 | 78 |
| Levothyroxine Sodium | Levothyroxine Sodium | 431 | 64 |
| Gabapentin | Gabapentin | 400 | 80 |
| Vascepa | Icosapent Ethyl | 386 | 47 |
| Linzess | Linaclotide | 376 | 54 |
| Ezetimibe | Ezetimibe | 374 | 65 |
| Januvia | Sitagliptin Phosphate | 362 | 47 |
| Clopidogrel | Clopidogrel Bisulfate | 328 | 48 |
| Eliquis | Apixaban | 306 | 45 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 284 | 40 |
| Carvedilol | Carvedilol | 267 | 35 |
| Diclofenac Sodium | Diclofenac Sodium | 267 | 72 |
| Tamsulosin Hcl | Tamsulosin Hcl | 266 | 41 |
| Omeprazole | Omeprazole | 250 | 45 |
| Meloxicam | Meloxicam | 237 | 65 |
| Fluticasone Propionate | Fluticasone Propionate | 231 | 115 |
| Pravastatin Sodium | Pravastatin Sodium | 229 | 36 |
| Azithromycin | Azithromycin | 220 | 163 |
| Dexlansoprazole Dr | Dexlansoprazole | 218 | 30 |
| Sertraline Hcl | Sertraline Hcl | 211 | 25 |
| Atenolol | Atenolol | 209 | 32 |
| Synthroid | Levothyroxine Sodium | 208 | 34 |
| Simvastatin | Simvastatin | 207 | 28 |
| Pantoprazole Sodium | Pantoprazole Sodium | 204 | 41 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 202 | 32 |
| Dexilant | Dexlansoprazole | 188 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 182 | 37 |
| Furosemide | Furosemide | 181 | 46 |
| Memantine Hcl | Memantine Hcl | 177 | 23 |
| Montelukast Sodium | Montelukast Sodium | 175 | 37 |
| Zolpidem Tartrate | Zolpidem Tartrate | 174 | 44 |
| Creon | Lipase/Protease/Amylase | 171 | 28 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 170 | 27 |
| Metoprolol Tartrate | Metoprolol Tartrate | 168 | 25 |
| Ozempic | Semaglutide | 168 | 25 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 154 | 27 |
| Jardiance | Empagliflozin | 149 | 23 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 148 | 42 |
| Zenpep | Lipase/Protease/Amylase | 145 | 28 |
| Duloxetine Hcl | Duloxetine Hcl | 138 | 29 |
| Meclizine Hcl | Meclizine Hcl | 137 | 37 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 132 | 24 |
| Ranolazine Er | Ranolazine | 131 | 17 |
| Donepezil Hcl | Donepezil Hcl | 123 | 23 |
| Finasteride | Finasteride | 119 | 18 |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 119 | 22 |
| Dicyclomine Hcl | Dicyclomine Hcl | 117 | 56 |
| Prednisone | Prednisone | 112 | 73 |
| Xarelto | Rivaroxaban | 112 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 111 | 23 |
| Crestor | Rosuvastatin Calcium | 107 | 11 |
| Ztlido | Lidocaine | 107 | 22 |
| Myrbetriq | Mirabegron | 96 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 94 | 22 |
| Nexium | Esomeprazole Magnesium | 92 | 13 |
| Valsartan | Valsartan | 91 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 90 | 16 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 86 | 17 |
| Icosapent Ethyl | Icosapent Ethyl | 85 | 18 |
| Farxiga | Dapagliflozin Propanediol | 84 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 82 | 46 |
| Breo Ellipta | Fluticasone/Vilanterol | 78 | 13 |
| Edarbi | Azilsartan Medoxomil | 78 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 77 | 11 |
| Nurtec Odt | Rimegepant Sulfate | 73 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 72 | 15 |
| Tradjenta | Linagliptin | 71 | suppressed |
| Allopurinol | Allopurinol | 70 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 70 | suppressed |
| Glimepiride | Glimepiride | 67 | suppressed |
| Pregabalin | Pregabalin | 66 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 66 | suppressed |
| Methylprednisolone | Methylprednisolone | 64 | 61 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 62 | 13 |
| Metoclopramide Hcl | Metoclopramide Hcl | 60 | 25 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 60 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 59 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 59 | 11 |
| Enalapril Maleate | Enalapril Maleate | 58 | suppressed |
| Lisinopril | Lisinopril | 58 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 57 | 53 |
| Labetalol Hcl | Labetalol Hcl | 56 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 56 | 15 |
| Propranolol Hcl | Propranolol Hcl | 55 | 16 |
| Diovan | Valsartan | 54 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 51 | 13 |
| Tribenzor | Olmesartan/Amlodipin/Hcthiazid | 51 | suppressed |
| Levofloxacin | Levofloxacin | 50 | 44 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 48 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 48 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 46 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 46 | 21 |
| Repaglinide | Repaglinide | 46 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 45 | 11 |
| Jentadueto | Linagliptin/Metformin Hcl | 45 | suppressed |
| Lexapro | Escitalopram Oxalate | 45 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 44 | 15 |
| Alprazolam | Alprazolam | 44 | 16 |
| Colchicine | Colchicine | 42 | suppressed |
| Lidocaine | Lidocaine | 42 | suppressed |
| Celebrex | Celecoxib | 41 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 41 | suppressed |
| Benicar | Olmesartan Medoxomil | 40 | suppressed |
| Plavix | Clopidogrel Bisulfate | 40 | suppressed |
| Entresto | Sacubitril/Valsartan | 39 | suppressed |
| Flomax | Tamsulosin Hcl | 39 | suppressed |
| Glipizide | Glipizide | 39 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 39 | 31 |
| Potassium Chloride | Potassium Chloride | 39 | suppressed |
| Prolia | Denosumab | 39 | 26 |
| Quetiapine Fumarate | Quetiapine Fumarate | 39 | suppressed |
| Ibuprofen | Ibuprofen | 38 | 31 |
| Repatha Sureclick | Evolocumab | 38 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 38 | suppressed |
| Bystolic | Nebivolol Hcl | 37 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 36 | 31 |
| Diclofenac Epolamine | Diclofenac Epolamine | 36 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 36 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 36 | 13 |
| Spironolactone | Spironolactone | 35 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 34 | suppressed |
| Loperamide | Loperamide Hcl | 34 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 34 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 34 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 33 | suppressed |
| Glumetza | Metformin Hcl | 33 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 32 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 32 | 16 |
| Telmisartan | Telmisartan | 32 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 31 | suppressed |
| Jublia | Efinaconazole | 31 | suppressed |
| Nitroglycerin | Nitroglycerin | 31 | 12 |
| Trulance | Plecanatide | 31 | suppressed |
| Ubrelvy | Ubrogepant | 31 | suppressed |
| Nystatin | Nystatin | 30 | 13 |
| Valacyclovir | Valacyclovir Hcl | 29 | 18 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Irbesartan | Irbesartan | 28 | suppressed |
| Ondansetron Odt | Ondansetron | 28 | 15 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Alcohol Swab | Alcohol Antiseptic Pads | 27 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 27 | suppressed |
| Repatha Syringe | Evolocumab | 27 | suppressed |
| Ciprofloxacin-Dexamethasone | Ciprofloxacin Hcl/Dexameth | 26 | 11 |
| Clobetasol Propionate | Clobetasol Propionate | 26 | suppressed |
| Olanzapine | Olanzapine | 26 | suppressed |
| Airsupra | Albuterol Sulfate/Budesonide | 25 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 25 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 25 | suppressed |
| Febuxostat | Febuxostat | 25 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 25 | suppressed |
| Cozaar | Losartan Potassium | 24 | suppressed |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 24 | suppressed |
| Sotalol | Sotalol Hcl | 24 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 24 | suppressed |
| Bumetanide | Bumetanide | 23 | suppressed |
| Clonidine | Clonidine | 23 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 23 | suppressed |
| Pepcid | Famotidine | 23 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 23 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 22 | suppressed |
| Brilinta | Ticagrelor | 22 | suppressed |
| Celecoxib | Celecoxib | 22 | suppressed |
| Bupropion Xl | Bupropion Hcl | 21 | suppressed |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 21 | suppressed |
| Trulicity | Dulaglutide | 21 | suppressed |
| Avodart | Dutasteride | 20 | suppressed |
| Clonazepam | Clonazepam | 20 | 12 |
| Norvasc | Amlodipine Besylate | 20 | suppressed |
| Qulipta | Atogepant | 20 | suppressed |
| Sucralfate | Sucralfate | 20 | suppressed |
| Benicar Hct | Olmesartan/Hydrochlorothiazide | 19 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 19 | suppressed |
| Dutasteride | Dutasteride | 19 | suppressed |
| Fluconazole | Fluconazole | 19 | 13 |
| Metformin Hcl Er | Metformin Hcl | 19 | suppressed |
| Mounjaro | Tirzepatide | 19 | suppressed |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 19 | 12 |
| Chlorthalidone | Chlorthalidone | 18 | suppressed |
| Nifedipine Er | Nifedipine | 18 | suppressed |
| Rayos | Prednisone | 18 | suppressed |
| Silodosin | Silodosin | 18 | suppressed |
| Naproxen | Naproxen | 17 | suppressed |
| Nateglinide | Nateglinide | 17 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 17 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 17 | suppressed |
| Toprol Xl | Metoprolol Succinate | 17 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 16 | suppressed |
| Lubiprostone | Lubiprostone | 16 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Folic Acid | Folic Acid | 15 | suppressed |
| Mirtazapine | Mirtazapine | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Dutasteride-Tamsulosin | Dutasteride/Tamsulosin Hcl | 14 | suppressed |
| Glipizide Er | Glipizide | 14 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Methimazole | Methimazole | 14 | suppressed |
| Mupirocin | Mupirocin | 14 | suppressed |
| Procto-Med Hc | Hydrocortisone | 14 | suppressed |
| Zetia | Ezetimibe | 14 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 13 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | 13 |
| Eplerenone | Eplerenone | 13 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 13 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 13 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Cephalexin | Cephalexin | 12 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 12 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 12 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 12 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 12 | 12 |
| Pioglitazone-Metformin | Pioglitazone Hcl/Metformin Hcl | 12 | suppressed |
| Prevacid | Lansoprazole | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Rapaflo | Silodosin | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Welchol | Colesevelam Hcl | 12 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 11 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 11 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 11 | suppressed |
| Invokana | Canagliflozin | 11 | suppressed |
| Meloxicam | Meloxicam, Submicronized | 11 | suppressed |
| Otezla | Apremilast | 11 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 11 | suppressed |
| Rybelsus | Semaglutide | 11 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 11 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,081.85 · 116 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, CAMZYOS, CREON, Cologuard Collection Kit, ELIQUIS, EVENITY, FARXIGA, Flector, IBSRELA, Korlym, LINZESS, Leqembi, Licart, NEXLETOL, NURTEC ODT, NUZYRA, OTEZLA, Ohtuvayre, Ozempic, PROLIA, QULIPTA, REPATHA, Rybelsus, Symbravo, TRELEGY ELLIPTA, Tirosint, UBRELVY, VOQUEZNA, VOWST, VRAYLAR, Veozah, XIFAXAN, ZAVZPRET, ZENPEP, ZORYVE, ZTLido | 23 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Airsupra play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error